Enlicitide
The first PCSK9 inhibitor taken as a pill: a macrocyclic peptide that lowered LDL cholesterol by more than half in phase 3
Enlicitide is an oral macrocyclic peptide from Merck that binds PCSK9, the protein that marks LDL receptors for destruction, so more receptors stay on liver cells to clear LDL cholesterol. In its phase 3 trial of 2,909 adults on statins, it lowered LDL cholesterol by about 56% more than placebo. Approved July 15, 2026.
Manufacturer's recommended dosing (FDA label): 20 mg, Once daily, in the morning on an empty stomach, Oral Details ↓
Recommended Dosing
Manufacturer's recommended dosing (FDA label)
From the prescribing information. Other doses studied, if any, are in the full dosing data below.
What is it?
PCSK9 is a liver protein that binds LDL receptors and sends them to be destroyed; fewer receptors means more LDL cholesterol left in the blood. The earlier PCSK9 medicines are injected antibodies. Enlicitide is a macrocyclic peptide engineered to bind PCSK9 and survive being swallowed.
Getting a peptide through the gut is the hard part. Its designers built it from modular fragments to reach picomolar potency and enough stability, and the tablet includes sodium caprate to help absorption. Even so, only about 1% of each dose is absorbed, and food 30 minutes beforehand roughly halves what gets in. That is why the dosing rules are strict.
In CORALreef Lipids, 2,909 adults already taking statins, with atherosclerotic disease or at high risk, saw LDL cholesterol fall 57.1% at week 24 against a 3.0% rise on placebo. In people with heterozygous familial hypercholesterolaemia, the fall was 58.2% against a 2.6% rise, sustained at week 52. Against other oral add-ons it lowered LDL by 64.6% in 56 days, compared with 27.8% for ezetimibe and 36.5% for bempedoic acid plus ezetimibe.
Pooled across four trials and 3,894 people, LDL fell about 56 percentage points more than on placebo, apoB 48 and lipoprotein(a) about 23. The size of that lipoprotein(a) drop is similar to the injected PCSK9 drugs. What is not yet known is whether it prevents heart attacks and strokes: the label rests on LDL lowering, and the outcomes trial, CORALreef Outcomes, is still running.
FDA approved it as Lipfendra on July 15, 2026, for adults with hypercholesterolaemia including the familial form, alongside diet and exercise. The recommended dose is one 20 mg tablet each morning on an empty stomach, with water, black coffee or plain tea, and nothing else for 30 minutes. The label lists no contraindications; diarrhoea and dizziness were the commonest adverse reactions in the familial trial. It has no EU authorisation yet.
Mechanism of Action
Enlicitide is an oral macrocyclic peptide that binds PCSK9 and stops it marking LDL receptors for destruction, so the liver clears more LDL cholesterol (label).
PCSK9 blocked
Binds PCSK9 and prevents it from attaching to LDL receptors on liver cells (label).
More LDL receptors
With PCSK9 blocked, more LDL receptors stay available on liver cells to clear LDL cholesterol from the blood (label).
Built to be swallowed
Sodium caprate in the tablet aids absorption; bioavailability is about 1%, steady state comes in about 7 days, and the effective half-life is about 14 hours (label).
Published Research
The trials behind enlicitide, from PubMed abstracts.
CORALreef Lipids: 2,909 adults on statins
LDL cholesterol changed by -57.1% at week 24 on enlicitide against +3.0% on placebo, a between-group difference of -55.8 percentage points; mean baseline LDL was 96.1 mg/dL.
Heterozygous familial hypercholesterolaemia: 303 adults
On background statins (and ezetimibe in 64.4%), LDL fell 58.2% at week 24 against a 2.6% rise on placebo (difference -59.4%), and 55.3% against an 8.7% rise at week 52.
Against oral non-statin add-ons
In 301 statin-treated adults, LDL fell 64.6% in 56 days on enlicitide against 6.3% on bempedoic acid, 27.8% on ezetimibe and 36.5% on both; adverse events were similar.
Phase 2b dose-finding
In 380 treated participants, LDL fell by 41.2%, 55.7%, 59.1% and 60.9% against placebo at week 8 on 6, 12, 18 and 30 mg; adverse events occurred at similar rates to placebo.
Commentary on the phase 3 trials
A commentary on CORALreef Lipids and CORALreef HeFH summarised LDL lowering of about 56% to 60% on top of background therapy, sustained through 24 to 52 weeks, with safety comparable to placebo and efficacy similar to antibody PCSK9 inhibitors.
Expert review: where it fits
A review of the phase 2 and 3 programme called enlicitide a promising way to widen access to PCSK9 inhibition by mouth, but said its definitive role depends on cardiovascular outcomes, long-term safety, real-world adherence and cost.
Meta-analysis of four trials
Across four randomised trials with 3,894 participants, LDL cholesterol fell 55.8 percentage points more than on placebo, apoB 48.0, non-HDL cholesterol 49.4 and lipoprotein(a) 22.7; discontinuation for adverse events was uncommon.
Lipoprotein(a) across PCSK9 drugs
Pooling 31 trials, PCSK9 antibodies and inclisiran lowered lipoprotein(a) by about 26% with no significant difference between them; enlicitide showed a similar reduction of about 25%, from too few trials for a head-to-head test.
How it was designed
Merck's chemists describe building enlicitide (MK-0616) by modular fragment assembly to fix an earlier lead's oxidation, solubility and manufacturing problems, arriving at a macrocycle with low-picomolar potency against PCSK9.
Dosing Data
Lipfendra is one 20 mg tablet taken each morning on an empty stomach with water, black coffee or plain tea, swallowed whole, with no other food or drink for 30 minutes.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
The approved product, as its label describes it:
- Lipfendra (tablet): Tablets: 20 mg enlicitide. Forms the label lists: tablets.
Source: Lipfendra (tablet) label, section 3 (DailyMed version 2, effective July 15, 2026).
Mixing a vial: a worked example
Nothing to mix: the label gives Lipfendra (tablet) as tablets, ready to use.
Source: Lipfendra (tablet) label, sections 2, 3 and 16 (DailyMed version 2, effective July 15, 2026).
Storage before and after mixing
Before mixing or first use: “Store LIPFENDRA at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).” “Store and dispense LIPFENDRA in the original bottle and keep the bottle tightly closed to protect from moisture.”
After mixing or first use: the label sentences we read say nothing separate about this.
Source: Lipfendra (tablet) label, sections 16 and 2 (DailyMed version 2, effective July 15, 2026).
How it is taken
As the approved label gives it: Oral (Once daily, in the morning on an empty stomach; Label: adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia).
Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: a half-life of effective about 14 hours; terminal about 244 hours. After about five half-lives almost none is left.
How long the doses were given: Label: adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia: Ongoing; LDL can be checked from 4 weeks.
When effects appear: unknown; no source on this page gives a time to effect for Enlicitide. Results reported in the studies are under Published Research.
Source: half-life: Lipfendra prescribing information, section 12.3 (DailyMed version 2, effective July 15, 2026; read September 30, 2026); Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Adverse reactions similar in frequency to placebo in the hypercholesterolaemia trials; Diarrhoea and dizziness, the most common in the familial hypercholesterolaemia trial; No contraindications listed on the label. Full list and cautions ↓
When to stop or get help: unknown; the label's warnings summary we read gives no rule for stopping Enlicitide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the Lipfendra label and the trials above”).
Interactions
Unknown: a PubMed search for human interaction studies of Enlicitide (reviewed 2026-09-30) found none. Unknown is not the same as safe to combine.
Every peptide's record, with its source: the interaction matrix.
Checking what you bought
Unknown: no published independent test of Enlicitide products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Enlicitide's expected mass, 1,550.8 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: FDA Approved (FDA: LIPFENDRA (enlicitide decanoate) tablets, NDA 220848 (Merck Sharp & Dohme), approved July 15, 2026 as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (Drugs@FDA). Sport: Not on the 2026 List.
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the Lipfendra label and the trials above.
Contraindications & Cautions
From the label; a clinician decides.
Legal Status
Enlicitide is an FDA-approved prescription medicine.
Frequently Asked Questions
?What is enlicitide?
An oral PCSK9 inhibitor from Merck, sold as Lipfendra: a macrocyclic peptide that helps the liver clear LDL cholesterol. It is taken as one 20 mg tablet a day.
?How much does it lower LDL cholesterol?
In its phase 3 trial of 2,909 adults on statins, by about 56 percentage points more than placebo at 24 weeks; in familial hypercholesterolaemia, by about 59 points.
?How do you take it?
One tablet each morning on an empty stomach, swallowed whole with water, black coffee or plain tea, then nothing else for at least 30 minutes.
?Why does it have to be taken on an empty stomach?
Only about 1% of each dose is absorbed. Taking it 30 minutes after a meal cut exposure roughly in half in the label's studies, while black coffee or plain tea made no meaningful difference. So it is taken first thing, and nothing but water, black coffee or plain tea for 30 minutes.
?Does it prevent heart attacks?
That has not been shown yet. The approval rests on lowering LDL cholesterol; the outcomes trial, CORALreef Outcomes, is still under way.
?Can it be taken with a statin?
Yes. In CORALreef Lipids, 97% of participants were already on a statin, and the label says it can be taken with other medications. It is meant as an add-on when LDL stays too high.
?How quickly does it work?
The label says the LDL-lowering effect can be measured from about 4 weeks after starting. In the trial against other oral add-ons, LDL had fallen 64.6% by day 56.
?How does it compare with injected PCSK9 drugs?
No head-to-head trial has been published. A commentary on the phase 3 trials judged its efficacy similar to the antibody PCSK9 inhibitors, and a meta-analysis found its lipoprotein(a) reduction, about 25%, similar to theirs. Its role, one review notes, will depend on outcomes data and cost.
References
- [fda-pi] Merck Sharp & Dohme. LIPFENDRA (enlicitide) tablets, US prescribing information: indication, dosage (20 mg once daily on an empty stomach), no contraindications, mechanism and pharmacokinetics (effective half-life about 14 hours, terminal about 244 hours), CORALreef trials. DailyMed set 100ec543, version 2, effective July 15, 2026; read September 30, 2026.
- [pubmed] Navar AM, et al. "A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide." N Engl J Med, 2026;394(6):529-539. PMID: 41879224.
- [pubmed] Ballantyne CM, et al. "Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial." JAMA, 2026;335(2):129-139. PMID: 41206969.
- [pubmed] Catapano AL, et al. "Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial." J Am Coll Cardiol, 2026;88(3):340-352. PMID: 42017875.
- [pubmed] Ballantyne CM, et al. "Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616." J Am Coll Cardiol, 2023;81(16):1553-1564. PMID: 36889610.
- [fda] FDA. Drugs@FDA (openFDA): LIPFENDRA NDA 220848, approved July 15, 2026; and FDA, Novel Drug Approvals for 2026 (content current as of September 28, 2026). Read September 30, 2026.
- [other] European Medicines Agency. Medicines register: no entry for enlicitide. Read September 30, 2026.
- [pubmed] Yagmur B, et al. "Enlicitide, a Novel Oral Macrocyclic Peptide PCSK9 Inhibitor for Lipid Lowering: A Systematic Review and Meta-Analysis." J Cardiovasc Dev Dis, 2026;13(8). PMID: 42645869.
- [pubmed] Mulligan MD, et al. "Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials." J Clin Lipidol, 2026;20(6):1054-1064. PMID: 42025558.
- [pubmed] Josien H, et al. "Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, through Issue-Driven Fragment-Based Synthetic Assembly and SAR." J Med Chem, 2026;69(11):13473-13491. PMID: 42201324.
- [pubmed] Müller-Kozarez I, et al. "Phase 3 study results for oral PCSK9 inhibition with enlicitide." Med, 2026;7(4):101097. PMID: 41966715.
- [pubmed] Ballantyne CM, et al. "Evaluating enlicitide decanoate: first oral PCSK9 inhibitor for the treatment of adults with hypercholesterolemia." Expert Opin Pharmacother, 2026:1-11. PMID: 42709041.
Sources & Citations
Studies were read from their PubMed abstracts; the Lipfendra label (DailyMed version 2, effective July 15, 2026) was read October 6, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.